LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTC:IMUC) (IMUC), a biotechnology company, today announced that recently completed proof-of-principle studies demonstrate efficacy of its cancer stem cell vaccine technology in treating glioblastoma, a form of brain cancer, in preclinical animal models. The company is planning to submit an Investigational New Drug (IND) application to the FDA later this year to commence a Phase I clinical trial for its cancer stem cell vaccine product, ICT-111, to treat glioblastoma. The company’s cancer stem cell vaccine technology also could be applicable for multiple other cancers.
